Basking Biosciences doses first subject in Phase II acute ischaemic stroke trial
Basking Biosciences has initiated the Phase II RAISE trial of BB-031 for acute ischaemic stroke, aiming to assess safety, tolerability, and preliminary efficacy. The trial will enrol 156 patients within 24 hours of stroke onset, with a Data Safety Monitoring Committee overseeing the study. BB-031 targets von Willebrand Factor using RNA aptamer technology, aiming to expand therapeutic options for stroke patients.
Reference News
Basking Biosciences has initiated the Phase II RAISE trial of BB-031 for acute ischaemic stroke, aiming to assess safety, tolerability, and preliminary efficacy. The trial will enroll 156 patients within 24 hours of stroke onset, with a Data Safety Monitoring Committee overseeing the study. BB-031 targets von Willebrand Factor using RNA aptamer technology, with a reversal agent, BB-025, planned for clinical development.
Basking Biosciences has initiated the Phase II RAISE trial of BB-031 for acute ischaemic stroke, aiming to assess safety, tolerability, and preliminary efficacy. The trial will enrol 156 patients within 24 hours of stroke onset, with a Data Safety Monitoring Committee overseeing the study. BB-031 targets von Willebrand Factor using RNA aptamer technology, aiming to expand therapeutic options for stroke patients.